- Home
- DBVT vs XPEL Comparison
DBVT vs XPEL Comparison
Compare DBVT & XPEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DBVT | XPEL |
|---|---|---|
| Founded | 2002 | 1999 |
| Country | France | United States |
| Employees | 90 | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Industrial Specialties |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.3B |
| IPO Year | 2014 | 2019 |
Fundamental Metrics
Financial Performance| Metric | DBVT | XPEL |
|---|---|---|
| Price | $20.54 | $46.59 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 1 |
| Target Price | $32.04 | ★ $56.00 |
| AVG Volume (30 Days) | ★ 234.3K | 232.5K |
| Earning Date | 04-30-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 10.26 | ★ 12.12 |
| EPS | N/A | ★ 1.85 |
| Revenue | $5,636,000.00 | ★ $476,200,000.00 |
| Revenue This Year | $35.04 | $12.64 |
| Revenue Next Year | $2,360.78 | $11.98 |
| P/E Ratio | ★ N/A | $25.21 |
| Revenue Growth | ★ 35.77 | 13.27 |
| 52 Week Low | $7.53 | $27.17 |
| 52 Week High | $26.19 | $55.91 |
Technical Indicators
Market Signals| Indicator | DBVT | XPEL |
|---|---|---|
| Relative Strength Index (RSI) | 49.54 | 58.75 |
| Support Level | $20.23 | $31.55 |
| Resistance Level | $23.52 | $55.36 |
| Average True Range (ATR) | 0.93 | 1.61 |
| MACD | -0.10 | 0.09 |
| Stochastic Oscillator | 35.62 | 48.54 |
Price Performance
Historical ComparisonAbout DBVT DBV Technologies S.A.
DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.
About XPEL XPEL Inc.
XPEL Inc is a supplier of protective films, coatings, and related services principally to the automobile aftermarket, new car dealerships, and automobile original equipment manufacturers, or OEMs. The majority of its revenue is derived from Product, which includes Paint protection film and Window film. The company derives revenue from Service, which includes Software, Cutbank credits, and Installation labor. The majority of revenue is derived from the United States.